Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin Alone or in Combination With Other Therapies in Urothelial Cancer
NCT03288545Phase 2Terminated
- Sponsor
- Astellas Pharma
- Start
- Oct 2017
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of enfortumab vedotin in urothelial carcinoma (UC), bladder cancer, renal pelvis cancer, ureteral cancer, urethral cancer, sponsored by Astellas Pharma. Started Oct 2017; status: terminated.
02
Drugs
enfortumab vedotin
03
Conditions
urothelial carcinoma (UC)bladder cancerrenal pelvis cancerureteral cancerurethral cancer
Beyond the preview
Go deeper on NCT03288545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03288545.